uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
24.83
-0.47 (-1.86%)
At close: Oct 30, 2026, 4:00 PM EST
26.27
+1.44 (5.80%)
Pre-market: Nov 2, 2026, 8:21 AM EST
uniQure Revenue
uniQure had revenue of $5.84M in the quarter ending June 30, 2026, with 11.00% growth. This brings the company's total for the last twelve months to $18.67M, up 30.24% year-over-year. In the year 2025, uniQure had annual revenue of $16.10M, down -40.64%. That makes uniQure the 34,217th largest company in the world by revenue and 4,493rd in the United States.
Revenue (ttm)
$18.67M
Revenue Growth
+30.24%
P/S Ratio
92.24
Revenue / Employee
$84,489
Employees
221
Market Cap
1.72B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.10M | -11.02M | -40.64% |
| Dec 31, 2024 | 27.12M | 11.28M | 71.17% |
| Dec 31, 2023 | 15.84M | -90.64M | -85.12% |
| Dec 31, 2022 | 106.48M | -417.52M | -79.68% |
| Dec 31, 2021 | 524.00M | 486.49M | 1,296.82% |
| Dec 31, 2020 | 37.51M | 30.23M | 415.23% |
| Dec 31, 2019 | 7.28M | -4.00M | -35.48% |
| Dec 31, 2018 | 11.28M | -1.82M | -13.91% |
| Dec 31, 2017 | 13.11M | -11.99M | -47.78% |
| Dec 31, 2016 | 25.10M | 14.52M | 137.27% |
| Dec 31, 2015 | 10.58M | 4.44M | 72.25% |
| Dec 31, 2014 | 6.14M | 2.09M | 51.74% |
| Dec 31, 2013 | 4.05M | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | 68.42K | -174.98K | -71.89% |
| Dec 31, 2005 | 243.40K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Novavax | 413.80M |
| Nuvation Bio | 169.90M |
| Agios Pharmaceuticals | 98.34M |
| Intellia Therapeutics | 59.51M |
| Stoke Therapeutics | 28.21M |
| Maze Therapeutics | 20.00M |
| Zenas BioPharma | 1.00M |
QURE News
- 43 minutes ago - uniQure announces FDA acceptance, priority review for ifezuntirgene inilparvovec - TheFly
- 1 hour ago - uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington's Disease - GlobeNewsWire
- 5 days ago - uniQure to Announce Third Quarter 2026 Financial Results - GlobeNewsWire
- 18 days ago - uniQure assumed with a Buy at UBS - TheFly
- 4 weeks ago - uniQure downgraded to Equal Weight from Overweight at Barclays - TheFly
- 4 weeks ago - uniQure price target lowered to $48 from $65 at RBC Capital - TheFly
- 4 weeks ago - uniQure price target lowered to $31 from $46 at Goldman Sachs - TheFly
- 4 weeks ago - uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - PRNewsWire